Multimodality treatment of germ cell cancer patients who had progression or relapse after high dose chemotherapy and autologous bone marrow transplantation. 2007

T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
Department of Oncology, Bone Marrow Transplantation Unit, Military Institute of Health Services, Warsaw, Poland.

OBJECTIVE When a patient with germ cell tumor (GCT) fails to be cured with high dose chemotherapy (HDC) and autologous haematopoietic stem cell transplantation (auto- BMT) the overall prognosis is very poor and any further treatment has only palliative character. A question requiring answer is how intense should this kind of treatment be, and what can be expected from it. METHODS Of 44 patients with GCT who were transplanted after HDC in our centre between 1999- 2005, 17 experienced treatment failure. Amongst them 14 had marker-positive relapse or confirmed germ cell histology. Another 3 had second primary neoplasms. Of the 17 patients 14 received further treatment that consisted of surgery alone in 2, chemotherapy in 2, radiotherapy in 1, combined surgery + chemotherapy in 5, chemotherapy +surgery + radiotherapy in 3 and chemotherapy + radiotherapy in 1 patient. RESULTS The median survival from the time of relapse was 3 months in all patients, and 6 months in the 14 patients who received further treatment. In 6 patients with relapse confined to a single site the median survival was 11 months. Three patients in this group are alive with overall survival (OS) of 37.4+, 24.3+ and 6.2+ months (all had multimodal treatment: chemotherapy + surgery or radiotherapy, and all achieved durable complete response/CR). CONCLUSIONS Our results suggest that GCT patients who have relapsed/ progressed after HDC may benefit from further treatment. Best chances for long term survival have those who experience relapse confined to one metastatic site and receive combined treatment (surgery or radiotherapy plus systemic therapy).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009373 Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS. Germ Cell Cancer,Germ Cell Tumor,Neoplasms, Embryonal and Mixed,Cancer, Embryonal,Cancer, Embryonal and Mixed,Embryonal Neoplasms,Germ Cell Neoplasms,Germ Cell and Embryonal Neoplasms,Germ Cell and Embryonic Neoplasms,Neoplasms, Embryonal,Neoplasms, Germ Cell,Neoplasms, Germ Cell and Embryonic,Cancer, Germ Cell,Cancers, Embryonal,Cancers, Germ Cell,Embryonal Cancer,Embryonal Cancers,Embryonal Neoplasm,Germ Cell Cancers,Germ Cell Tumors,Neoplasm, Embryonal,Tumor, Germ Cell,Tumors, Germ Cell
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
April 1997, Cancer,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
October 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
November 1997, Bone marrow transplantation,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
January 1989, Nihon Gan Chiryo Gakkai shi,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
October 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
September 1993, British journal of cancer,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
September 1984, Cancer,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
November 1997, Bone marrow transplantation,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
January 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
T Sarosiek, and P Rzepecki, and P Langiewicz, and J Zolnierek, and J Barzal, and C Szczylik
March 1990, Japanese journal of clinical oncology,
Copied contents to your clipboard!